semaj83/ctmatch_classification huggingface dataset:
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Vulvar Cancer Cervical Cancer Vulvar Dysplasia Cervical Dysplasia Anal Cancer Anal Dysplasia HPV-Related Anal Squamous Cell Carcinoma Women age ≥ 40 Previous diagnosis of VIN 2/3 or vulvar  Women with a previous diagnosis of cancer aside from basal cell carcinoma of the skin, cervical cancer, or vulvar cancer Women who are HIV positive Women currently taking immunosuppressant medication Women who have had a previous hysterectomy
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-29.0,  Contraception The subject has signed and dated the Informed Consent Form (ICF) The subject is healthy when requesting contraception The subject is between 18 years of age (inclusive) at the time of signing the ICF The subject has normal or clinically insignificant cervical smear for oncocytology (i.e. Pap test) not requiring further follow up (a cervical smear has to be taken at the Screening Visit [Visit 1] or a normal result has to have been documented within the previous 6 months) The subject has a history of regular (i.e., endogenous cyclicity without hormonal contraceptive use) cyclic menstrual periods (length of cycle 21 days), as confirmed by the subject The subject is willing and able to attend the scheduled study visits and to comply with the study procedures  Pregnancy or current lactation (less than 6 weeks postpartum or since abortion before the Screening Visit) Infected abortion or postpartum endometritis within 3 months prior to the Screening Visit Chronic, daily use of drugs that may increase serum potassium levels Undiagnosed abnormal genital bleeding Acute cervicitis or vaginitis (until successfully treated) Lower urinary tract infection (until successfully treated) Acute or recurrent pelvic inflammatory disease or conditions associated with increased risk for pelvic infections Congenital or acquired uterine anomaly including fibroids, in the opinion of the investigator, which would interfere with insertion and/or retention of the intrauterine system (i.e., if they distort the uterine cavity) Cervical neoplasia, uterine or cervical malignancy, or sex hormone-dependent tumors History of migraine, focal migraine with asymmetrical visual loss or other symptoms indicating transient cerebral ischemia
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 50.0-80.0,  Knee Osteoarthritis Varus knee; degrees of extra articular deformity < 15°; Knee Osteoarthritis; Straight limited < 30°; range of knee flexion > 90°; No hip abnormalities  Valgus knee; degrees of extra articular deformity > 15°; Knee infection; Rheumatic arthritis; Ankylosing Spondylitis; Prior femoral surgery
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 19.0-40.0,  Fasting age 19-40 years Muslim men fasted completely during Ramadan no known of any metabolic-related diseases  any diseases intake of any medication and dietary supplement smoking alcohol drinking
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 25.0-45.0,  Cervical Intraepithelial Neoplasia HPV-Related Cervical Carcinoma Female aged 25 to 45 years at the time of the first vaccine dose Willing to comply with the requirements of the protocol (e.g., return for follow-up visits) Written informed consent prior to enrollment  Pregnant or breastfeeding. Women must be at least 3 months post-pregnancy and not breastfeeding to enter the study Planning to become pregnant or planning to discontinue contraceptive precautions during the first twelve months of the study (months 0-12) History of allergic disease, suspected allergy or reactions likely to be exacerbated by any component of the vaccine Any other medical condition or disease that could compromise the life of the participant during enrollment in the study Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days prior to the first dose of the study vaccine Previous vaccination against human papillomavirus History of cervical cancer or hysterectomy
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  High Grade Squamous Intra-epithelial Lesion (HSIL) Persistent high grade squamous intra-epithelial lesion (HSIL) which must meet all of the following i. Pathologically confirmed grade 2 or 3 AIN demonstrated by high resolution anoscopy with grade on each occasion re-confirmed at screening by nominated study pathologist from Douglas Hanly Moir (DHM) (pathology case review to be conducted prior to enrolment) ii. Lesion must have been visualised on at least three sequential occasions over at least 12 months, including the pre enrolment screening high resolution anoscopy (HRA). iii. Lesion must have persistent geographical characteristics consistent with a single lesion observed over time (as defined in the Manual of Operations). 2. No history of thromboembolic disease 3. No evidence of anal cancer or Superficially Invasive Squamous Cell Carcinoma of the Anus (SISCCA) 4. Willingness to use appropriate contraception (including refraining from sperm donation) 5. Age 18 years or older 6. Provision of written informed consent In addition, for subjects with HIV: 7. Adherence to a stable suppressive antiretroviral therapy (ART) regimen, unchanged for at least two months 8. CD4+ count ≥ 200 cells/µl 9. HIV viral load < 200 copies/mL for at least six months  Absolute neutrophil count (ANC) <1000 cells/μL 2. Haemoglobin <10.0 g/dL 3. Platelet count <75,000 cells/μL 4. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > three times upper limit of normal 5. Calculated or measured creatinine clearance (CLCr) ≤ 50 mL/min (calculated by Cockcroft-Gault formula) 6. Patients with significant cardiac dysfunction including congestive heart failure, NY Heart Association Class II; Myocardial infarction within 12 months of starting study; unstable of poorly controlled angina 7. Current pregnancy or breastfeeding 8. Any condition not already outlined above which, in the opinion of the clinical investigator, would place the subject at risk if they participated or would jeopardise adherence or follow up
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 25.0-65.0,  Uterine Cervical Neoplasms Women between 25 and 65 years old Met within Doctors of the World programs  History of total hysterectomy (= ablation of uterus and cervix) Never had sexual intercourse Last pap smear test made during the three last years (ou first pap smear test during the last year)
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lupus Erythematosus, Systemic SLE Objective I ≥4 American College of Rheumatology (ACR) or 3 ACR plus a typical histological lesion of SLE on renal or skin biopsy Clinician's diagnosis based on his/her assessment Patients from the Toronto Lupus Clinic with regular follow-up, defined as having follow up visits at 3 and 6 months from the baseline visit (1st study visit). Objective II: • Participant in the BLISS-52 and BLISS-76 trials Objective III ≥4 American College of Rheumatology (ACR) or 3 ACR plus a typical histological lesion of SLE on renal or skin biopsy Increase in ≥4 Clinician's diagnosis based on his/her assessment  Objective I and III Patients with missing follow up visits at 3 and 6 months from the baseline visit (1st study visit) Patients with missing data in the charts for all visits. Objective II: • Participants who did not complete the trial and therefore have missing data points for primary endpoint measures
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 20.0-60.0,  Cervical Dysplasia Suspicious cervix 2. Age between 20 to 60 years  Previously diagnosed cervical lesions. 2. Pregnant women
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Local Anaesthetic Complication Age greater than or equal to 18 years Patient requiring conization on the CHU of Montpellier or Nîmes and having chosen a local anesthesia Informed and not opposed to participate in this research  Contra-indication to local anesthesia
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 25.0-65.0,  Cervical Cancer The patients who are voluntary to accept screening with sexual life  uterectomy, cancer, other serious illness, physical examination(pregnant women are not exclusive)
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Cervical Cancer Cervical Abnormalities This protocol will de-identified images and clinical data from NCI studies
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) Vulvar Dysplasia Vulvar Intraepithelial Neoplasia (VIN) VIN2 VIN3 Pre-cancerous Lesions of the Vulva Human Papillomavirus (HPV) Women aged 18 and above Have high grade squamous intraepithelial lesion (HSIL) of the vulva (VIN2 or VIN3) caused by infection with HPV types 16 and/or 18 confirmed at screening visit  Biopsy-proven differentiated VIN Any previous treatment for vulvar HSIL within 4 weeks prior to screening Allergy to imiquimod 5% cream or to an inactive ingredient in imiquimod 5% cream Pregnant, breastfeeding or considering becoming pregnant within 6 months following the last dose of investigational product Immunosuppression as a result of underlying illness or treatment Significant acute or chronic medical illness
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Dysplasia Cervical High Grade Squamous Intraepithelial Lesion HSIL Women aged 18 years and above Confirmed cervical infection with HPV types 16 and/or 18 at screening Cervical tissue specimen/slides provided to Study Pathology Adjudication Committee for diagnosis scheduled to be collected within 10 weeks prior to anticipated date of first dose of study drug Confirmed histologic evidence of cervical HSIL at screening Must be judged by Investigator to be an appropriate candidate for the protocol-specified procedure required at Week 36 With respect to their reproductive capacity must be post-menopausal or surgically sterile or willing to use a contraceptive method with failure rate of less than 1% per year when used consistently and correctly from screening until Week 36 Normal screening electrocardiogram (ECG)  Microscopic or gross evidence of adenocarcinoma-in-situ (AIS), high grade vulvar, vaginal, or anal intraepithelial neoplasia or invasive cancer in any histopathologic specimen at screening Cervical lesion(s) that cannot be fully visualized on colposcopy History of endocervical curettage (ECC) which showed cervical HSIL indeterminate, or insufficient for diagnosis Treatment for cervical HSIL within 4 weeks prior to screening Pregnant, breastfeeding or considering becoming pregnant during the study History of previous therapeutic HPV vaccination Immunosuppression as a result of underlying illness or treatment Receipt of any non-study, non-live vaccine within 2 weeks of Day 0 Receipt of any non-study, live vaccine within 4 weeks of Day 0 Current or history of clinically significant, medically unstable disease or condition which, in the judgment of the investigator, would jeopardize the safety of the participant, interfere with study assessments or endpoint evaluation, or otherwise impact the validity of the study results
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Intraepithelial Neoplasia Intraepithelial Neoplasm, Cervical Cervical Cancer Neoplasm Cervix Women aged 18 years and older; 2. Women with abnormal cervical cytology (atypical squamous cells of undetermined significance or more severe interpretations [≥ASC-US]) or positive high-risk HPV test on cervical samples. Additionally, 10% of the study population will consist of women with no change in cervical cytology and HPV test in order to check verification bias (see further explanations in "6.2. Sample calculation"); 3. Women with intact cervix or previously submitted to LEEP (loop electrosurgical excision procedure), cone or cryotherapy, with the presence of the cervix; 4. Women of childbearing potential should have a negative urine or blood pregnancy test; 5. Ability to understand and willing to provide informed consent document  Women under 18 years old; 2. Women who have undergone hysterectomy with removal of the cervix; 3. Women with known allergy to proflavine or acriflavine; 4. Women who are pregnant or nursing at the time of enrollment; 5. Incapacitated women or in vulnerable situations or who are not willing to give consent; 6. Women who belong to the indigenous community
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 25.0-65.0,  Cervical Cancer Screening Self-identify as transgender male or as transmasculine Assigned female sex at birth English speaking ages 25-65 years report not having had a pap smear in the last three years if age 30 and over, report not having a Pap smear/HPV co-test in the past 5 years  • Those who report having had a hysterectomy Those who report having history of cervical cancer Adults unable to consent Those who are pregnant Prisoners
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 10.0-17.0,  Substance Use all students enrolled in participating class rooms  n/a
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Contrast-induced Nephropathy Participants, older than 18 years old and received contrast enhanced CT scan in the emergency medicine department The Mehran Risk Score is greater than 5 points  The Mehran Risk Score is under 6 points Participants who doesn't want to enroll the study
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Anal Carcinoma Anal Condyloma Female patients aged 18-65 years with an anatomic pathology compatible with CIN II / CIN III, without restriction regarding skin color, race, ethnicity, religion; Patients of the Oncology Gynecology Service of the HCSL, registered in the hospital management system, in outpatient consultations; Those who agree to participate in the study and sign the ICF. Patients attended at the general gynecological surgery outpatient clinic (control group) with no evidence of colpocitological alteration. -  Patients who withdraw the consent term. History of previous anal cancer / anal intraepithelial neoplasia. Immunosuppressed: HIV, SLE, users of immunosuppressive and transplanted drugs. -
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Schizophrenia Spectrum and Other Psychotic Disorders he/she currently uses CLZ or he/she has used CLZ in the past/will use CLZ he/she has received a diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder or psychotic disorder NOS his/her age must be ≥18 years old he/she must be able to speak and read the language of the Informed Consent (differs per country) he/she must be mentally competent and have decisional capacity with regard to a decision to participate in the current study  admission to a psychiatric unit involuntarily (not all countries) a history of Parkinson's disease
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Diet Modification men and pre-menopausal, non-pregnant or non-lactating women non-vegetarian non-smoking alcohol intake ≤8 drinks/week ≤5 h/week of moderate-vigorous exercise  acute or chronic GI illnesses, conditions, or issues history of GI surgical intervention chronic or current use of anti-hypertensive, lipid-lowering, anti-diabetic, analgesic, or laxative medications antibiotic treatment in the last 3 months use of fiber or probiotics supplements allergies or intolerances to fiber sources